influvac 15 mikrog ha / 0.5 ml injektioneste, suspensio, esitäytetty ruisku
mylan healthcare b.v. - influenssa a-viruksen h3n2, pinta-antigeeni, inaktivoitu,influenssa b-virus, pinta-antigeeni, inaktivoitu,influenssa a h1n1-virus, pinta-antigeeni, inaktivoitu - injektioneste, suspensio, esitäytetty ruisku - 15 mikrog ha / 0.5 ml - influenssarokote, puhdistettu antigeeni
engerix-b 20 mikrog/ml injektioneste, suspensio
glaxosmithkline biologicals sa - hepatiitti b-virus, pinta-antigeeni, rdna - injektioneste, suspensio - 20 mikrog/ml - hepatiitti b
equip f vet. injektioneste, suspensio
zoetis animal health aps - equine influenza virus, a/1, newmarket 77, surface antigen, equine influenza virus, a/2, kentucky 98, surface antigen, equine influenza virus, a/2, borlange, surface antigen - injektioneste, suspensio - hevosen influenssavirus -rokote
equip ft vet. injektioneste, suspensio
zoetis animal health aps - equine influenza virus, a/1, newmarket 77, surface antigen, equine influenza virus, a/2, borlange, surface antigen, tetanus toxoid, equine influenza virus, a/2, kentucky 98, surface antigen - injektioneste, suspensio - inaktivoitu hevosen influenssavirus -rokote + inaktivoitu klostridirokote
hexavac
sanofi pasteur msd, snc - puhdistettu difteriatoksoidi, puhdistettua tetanustoksoidia, puhdistettu hinkuyskä-kurkkumätä, puhdistettu hinkuyskä rihmamaiset hemagglutiniini -, hepatiitti b-pinta-antigeeni, inaktivoitu tyypin 1 poliovirus (mahoney), inaktivoitu tyypin 2 poliovirus (mef-1), inaktivoitu tyypin 3 poliovirus (saukett), haemophilus influenzae tyyppi b-polysakkaridia - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - rokotteet - tämä yhdistetty rokote on tarkoitettu ensisijainen ja kehua rokotusten lasten kurkkumätä, jäykkäkouristus, hinkuyskä, hepatiitti b aiheuttama kaikki tunnetut alatyyppejä, polio ja invasiivisia infektioita johtuu haemophilus influenzae tyyppi b.
agrippal 15 mikrog ha / 0.5 ml injektioneste, suspensio, esitäytetty ruisku
seqirus s.r.l. - influenssa a-viruksen h3n2, pinta-antigeeni, inaktivoitu,influenssa b-virus, pinta-antigeeni, inaktivoitu,influenssa a h1n1-virus, pinta-antigeeni, inaktivoitu - injektioneste, suspensio, esitäytetty ruisku - 15 mikrog ha / 0.5 ml - inaktivoitu influenssarokote (koko virus)
prehevbri
vbi vaccines b.v. - hepatiitti b-pinta-antigeeni - b-hepatiitti - rokotteet - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.
purevax rcpch felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
infanrix hexa
glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), hepatitis b surface antigen, poliovirus (inactivated) (type-1 (mahoney strain), type-2 (mef-1 strain), type-3 (saukett strain)), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - rokotteet - infanrix hexa on tarkoitettu ensisijainen ja kehua rokottaminen imeväisten kurkkumätä, jäykkäkouristus, hinkuyskä, hepatiitti b, polio ja sairaus aiheuttaa haemophilus influenzae tyyppi b.
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.